subpage banner


Gain Therapeutics to Present New Preclinical Data on Brain Penetrant Allosteric Regulators at the 14th Meeting of the European Working Group on Gaucher Disease

October 13, 2020 08:00 ET | Source: Gain Therapeutics

BETHESDA, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that it will present an oral poster on its brain penetrant structurally targeted allosteric regulators (STARs) for the treatment of neuronopathic Gaucher disease at the European Working Group on Gaucher Disease (EWGGD), being held virtually from October 12-13, 2020.

Oral Poster Presentation Details

Title Development of Brain Penetrant Non-Competitive Pharmacological Chaperones for the Treatment of Neuronopathic Gaucher Disease
Session Session 4 : Poster Highlights
Presenter Natàlia Pérez Carmona, Ph.D., Head of Biology, Gain Therapeutics
Date/Time: October 13, 2020 at 1:45-1:50 p.m. CET

Additional details can be found on the EWGGD website at A copy of the presentation materials will be made available on the Publications section of the Gain website following the conclusion of the presentation.

About Gain Therapeutics, Inc.

Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
For more information, visit

Forward-Looking Statements

Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding Gain Therapeutics, Inc. (Gain) expected use of the proceeds from the Series B financing round; the market opportunity for Gain’s product candidates; and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Gain’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Contact

Daniel Ferry
LifeSci Advisors, LLC
+1 617-430-7576
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact

Cait Williamson, Ph.D.
LifeSci Communications, LLC
+1 646-751-4366
This email address is being protected from spambots. You need JavaScript enabled to view it.